Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.
Name:
bitzegeio et al_final.pdf
Size:
1.188Mb
Format:
PDF
Description:
Open Access publication
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Bitzegeio, JuliaBankwitz, Dorothea
Hueging, Kathrin
Haid, Sibylle
Brohm, Christiane
Zeisel, Mirjam B
Herrmann, Eva
Iken, Marcus
Ott, Michael
Baumert, Thomas F
Pietschmann, Thomas
Issue Date
2010
Metadata
Show full item recordAbstract
Hepatitis C virus (HCV) naturally infects only humans and chimpanzees. The determinants responsible for this narrow species tropism are not well defined. Virus cell entry involves human scavenger receptor class B type I (SR-BI), CD81, claudin-1 and occludin. Among these, at least CD81 and occludin are utilized in a highly species-specific fashion, thus contributing to the narrow host range of HCV. We adapted HCV to mouse CD81 and identified three envelope glycoprotein mutations which together enhance infection of cells with mouse or other rodent receptors approximately 100-fold. These mutations enhanced interaction with human CD81 and increased exposure of the binding site for CD81 on the surface of virus particles. These changes were accompanied by augmented susceptibility of adapted HCV to neutralization by E2-specific antibodies indicative of major conformational changes of virus-resident E1/E2-complexes. Neutralization with CD81, SR-BI- and claudin-1-specific antibodies and knock down of occludin expression by siRNAs indicate that the adapted virus remains dependent on these host factors but apparently utilizes CD81, SR-BI and occludin with increased efficiency. Importantly, adapted E1/E2 complexes mediate HCV cell entry into mouse cells in the absence of human entry factors. These results further our knowledge of HCV receptor interactions and indicate that three glycoprotein mutations are sufficient to overcome the species-specific restriction of HCV cell entry into mouse cells. Moreover, these findings should contribute to the development of an immunocompetent small animal model fully permissive to HCV.Citation
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. 2010, 6:e1000978 PLoS Pathog.Journal
PLoS pathogensPubMed ID
20617177Type
ArticleLanguage
enISSN
1553-7374ae974a485f413a2113503eed53cd6c53
10.1371/journal.ppat.1000978
Scopus Count
The following license files are associated with this item:
Related articles
- Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection.
- Authors: Tong Y, Zhu Y, Xia X, Liu Y, Feng Y, Hua X, Chen Z, Ding H, Gao L, Wang Y, Feitelson MA, Zhao P, Qi ZT
- Issue date: 2011 Mar
- Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
- Authors: Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF
- Issue date: 2010 Apr
- Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.
- Authors: Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, Haid S, Catanese MT, Zeisel MB, Nicosia A, Baumert TF, Kaderali L, Pietschmann T
- Issue date: 2014 Nov
- Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
- Authors: Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL
- Issue date: 2003 Oct 24
- Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.
- Authors: Cowton VM, Angus AGN, Cole SJ, Markopoulou CK, Owsianka A, Dunlop JI, Gardner DE, Krey T, Patel AH
- Issue date: 2016 Aug 15